Pfizer: positive data for Xtandi
(CercleFinance.com) - Pfizer and Astellas Pharma yesterday announced positive preliminary results from the Embark Phase 3 trial evaluating Xtandi (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC or nmCSPC) at high risk of biochemical relapse (BCR).
The study met its primary endpoint with a statistically significant and clinically meaningful improvement in metastasis-free survival (MFS) for patients treated with Xtandi plus leuprolide compared to placebo plus leuprolide.
As the only new hormonal therapy approved for three prostate cancer disease states in the US, Xtandi has benefited hundreds of thousands of men, Pfizer said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The study met its primary endpoint with a statistically significant and clinically meaningful improvement in metastasis-free survival (MFS) for patients treated with Xtandi plus leuprolide compared to placebo plus leuprolide.
As the only new hormonal therapy approved for three prostate cancer disease states in the US, Xtandi has benefited hundreds of thousands of men, Pfizer said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.